TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15297848

Group type: EXPERIMENTAL
Intervention: THAL-DEX (Thalidomide 100mg/day, Dexamethasone 40mg days 1-4 of each month)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: THAL-DEX
Number of subjects: 120

Group type: COMPARATOR
Intervention: CC (Conventional Chemotherapy)
Number of subjects: 120
Study: 11309010

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1 mg/ml plus fentanyl 2 microg/ml administered via patient-controlled epidural analgesia (PCEA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ropivacaine 1 mg/ml plus fentanyl 2 microg/ml administered via continuous epidural infusion (CEI)
Number of subjects: 60
Study: 9389843

Group type: EXPERIMENTAL
Intervention: Tramadol 2 mg kg‐1 in 0.9% saline (group T)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bupivacaine 2 mg kg‐1 (group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Mixture of bupivacaine and tramadol (group BT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 7702421

Group type: EXPERIMENTAL
Intervention: Captopril treatment
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study: 3123153

Group type: EXPERIMENTAL
Intervention: latamoxef (4 g/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ceftriaxone (2 g/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: cefotaxime (4 g/day)
Number of subjects: 60
Study: 28585263

Group type: EXPERIMENTAL
Intervention: Interventional sialendoscopy followed by intraductal steroid irrigations (group A)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Interventional sialendoscopy alone (group B)
Number of subjects: 22
Study: 28031511

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) 15 mg/kg 15 minutes prior to surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study: 24158412

Group type: EXPERIMENTAL
Intervention: Appropriate antibiotic use according to local hospital guidelines
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Early intravenous-oral switching
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Lower tertile of QI sum score
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Upper tertile of QI sum score
Number of subjects: 1252
Study: 23703835

Group type: EXPERIMENTAL
Intervention: HP3 (35% protein, 3 meals/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HP6 (35% protein, 6 meals/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: TD3 (traditional intake, 3 meals/day)
Number of subjects: 30
Study: 21180082

Group type: EXPERIMENTAL
Intervention: Qingkailing Injection (QKL) plus Ertong Qingfei oral liquid
Number of subjects: 206

Group type: COMPARATOR
Intervention: Ribavirin injection plus compound guaiacol potassium sulfonale oral solution
Number of subjects: 206
Study: 19051852

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP10)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide (CP16)
Number of subjects: 92
Study: 16084850

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg once daily for 5 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily for 5 days
Number of subjects: 10
Study: 11880076

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy group
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Both groups (prostatectomy and control)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Prostatectomy group
Number of subjects: 228
Study: 10537956

Group type: EXPERIMENTAL
Intervention: Palliative treatment with gemcitabine in combination with best supportive care
Number of subjects: 184

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 184
Study: 7742905

Group type: EXPERIMENTAL
Intervention: 100,000 IU of vitamin D3
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 2285657

Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7301035

Group type: EXPERIMENTAL
Intervention: Tienilic acid (250 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Chlorothiazide (500 mg/day)
Number of subjects: 25
Study: 29654038

Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) performed by trained nurses
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) led by general practitioners (GPs)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 750
Study: 27780251

Group type: EXPERIMENTAL
Intervention: PADOK intervention
Number of subjects: 1565

Group type: COMPARATOR
Intervention: Control group (usual school programme)
Number of subjects: 1565
Study: 24742818

Group type: EXPERIMENTAL
Intervention: High blackcurrant juice drink (250ml, 4 times a day for 6 weeks)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Low blackcurrant juice drink (250ml, 4 times a day for 6 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (flavored water, 250ml, 4 times a day for 6 weeks)
Number of subjects: 66
Study: 22101900

Group type: EXPERIMENTAL
Intervention: High-dose (HD; 200 IU/kg/d)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Low-dose (LD; 50 IU/kg 3 times/week)
Number of subjects: 115
Study: 20421833

Group type: EXPERIMENTAL
Intervention: 5 mg·kg of anhydrous caffeine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2 mg·kg of anhydrous caffeine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 18291401

Group type: EXPERIMENTAL
Intervention: Oral misoprostol for prevention of PPH
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: Fewer than 4 prenatal visits
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: Lack of iron supplementation
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: Perineal tear and birth weight (unknown until second stage of labor)
Number of subjects: 1620
Study: 15746793

Group type: COMPARATOR
Intervention: Low-dose prednisone (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Steroid withdrawal (study group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (protocol biopsies)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Steroid withdrawal group (1 year follow-up)
Number of subjects: 60
Study: 14567157

Group type: EXPERIMENTAL
Intervention: Orlistat with a hypocaloric diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0
Study: 10893015

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cetirizine vs Loratadine
Number of subjects: 15
Study: 8630596

Group type: EXPERIMENTAL
Intervention: High-dose inhaled budesonide (1,600 micrograms/d)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Low-dose inhaled budesonide (400 micrograms/d)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Oral theophylline (600 mg/d)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (smokers)
Number of subjects: 85

Group type: COMPARATOR
Intervention: All three groups (including smokers)
Number of subjects: 85
Study: 1564656

Group type: EXPERIMENTAL
Intervention: Intracameral carbachol (0.01%)
Number of subjects: 162

Group type: COMPARATOR
Intervention: ECCE without carbachol
Number of subjects: 162

Group type: COMPARATOR
Intervention: ECCE with IOL implantation without carbachol
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: ECCE with or without IOL implantation
Number of subjects: 162
Study: 2857611

Group type: EXPERIMENTAL
Intervention: Idazoxan (RX 781094), an alpha 2-antagonist, administered at low intra-arterial doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Idazoxan (RX 781094), an alpha 2-antagonist, administered at higher doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compounds with mixed alpha 2- and alpha 1-antagonist properties
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Idazoxan on arterial segments in vitro
Number of subjects: 0
Study: 31355677

Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: FVIII prophylaxis
Number of subjects: 0
Study: 29582212

Group type: EXPERIMENTAL
Intervention: CSL112 (1.7, 3.4, or 6.8 g)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CSL112
Number of subjects: 44
Study: 27097165

Group type: EXPERIMENTAL
Intervention: Benralizumab 2 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Benralizumab 20 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Benralizumab 100 mg
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 25953301

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Untreated OSA
Number of subjects: 29

Group type: COMPARATOR
Intervention: Controls without OSA
Number of subjects: 29
Study: 22710579

Group type: EXPERIMENTAL
Intervention: Lactulose (Gp‐L, 30 ml three times per day)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Probiotics (Gp‐P, three capsules per day containing 112.5 billion viable lyophilized bacteria per capsule)
Number of subjects: 235

Group type: COMPARATOR
Intervention: No therapy (Gp‐N)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Lactulose (Gp‐L) vs Probiotics (Gp‐P)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: All groups (Gp‐L, Gp‐P, Gp‐N)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Psychometric tests
Number of subjects: 235
Study: 20406223

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levofloxacin 1000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levofloxacin 1500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study: 18706417

Group type: EXPERIMENTAL
Intervention: Ustekinumab (subcutaneous)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (subcutaneous)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ustekinumab (subcutaneous and intravenous)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ustekinumab (infliximab nonresponders)
Number of subjects: 104
Study: 15897167

Group type: EXPERIMENTAL
Intervention: Fluconazole for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Griseofulvin for 6 weeks
Number of subjects: 40
Study: 12698115

Group type: EXPERIMENTAL
Intervention: Infliximab (Remicade 3 mg/kg) intravenously over 2 hours
Number of subjects: 10
Study: 10596306

Group type: EXPERIMENTAL
Intervention: Selenium levels in patients with AMI
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: GSH-Px activity in patients with AMI
Number of subjects: 27
Study: 8550048

Group type: EXPERIMENTAL
Intervention: D-penicillamine (DPCA)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 222
Study: 1647955

Group type: EXPERIMENTAL
Intervention: Pharmacokinetically adjusted doses of metoclopramide
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard doses of metoclopramide adjusted to body weight
Number of subjects: 28
Study: 6420904

Group type: EXPERIMENTAL
Intervention: Inhalation anaesthetic technique (Group A)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Ketamine infusion technique (Group B)
Number of subjects: 65
Study: 31640435

Group type: EXPERIMENTAL
Intervention: Carfilzomib and dexamethasone (Kd56)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone (Vd-8)
Number of subjects: 0
Study: 30036412

Group type: EXPERIMENTAL
Intervention: Systemic steroid treatment
Number of subjects: 59

Group type: COMPARATOR
Intervention: No steroid treatment
Number of subjects: 59
Study: 26681680

Group type: EXPERIMENTAL
Intervention: S-1 plus oral leucovorin (LV) at 40, 50, or 60 mg according to body surface area plus LV 25 mg, both given orally twice daily for 1 week, repeated every 2 weeks (SL group)
Number of subjects: 142

Group type: COMPARATOR
Intervention: S-1 monotherapy at the same dose as the SL group for 4 weeks, repeated every 6 weeks (S-1 group)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: S-1 plus oral leucovorin (LV)
Number of subjects: 142

Group type: COMPARATOR
Intervention: S-1 monotherapy
Number of subjects: 142
Study: 25234803

Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No event during weeks 1-12
Number of subjects: 0

Group type: COMPARATOR
Intervention: HCRU events
Number of subjects: 0

Group type: COMPARATOR
Intervention: EXACT-unreported events
Number of subjects: 0
Study: 19543081

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 24
Study: 15790675

Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g (i.v. acetaminophen 1 g formulation) administered as a 2-min bolus injection (n=50)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g (i.v. acetaminophen 1 g formulation) administered as a 15-min infusion (n=50)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Oral acetaminophen 1 g (n=50)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 175
Study: 12213864

Group type: EXPERIMENTAL
Intervention: Thyroid hormone suppressive therapy for longer than 6 months
Number of subjects: 346

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 346
Study: 9140241

Group type: EXPERIMENTAL
Intervention: AHA-recommended technique (apex-to-anterior electrode placement, no smearing of gel between electrodes)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Electrode paddles adjacent, gel smeared between electrodes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Post-exercise measurements
Number of subjects: 10
Study: 7945732

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 13
Study: 3285812

Group type: EXPERIMENTAL
Intervention: Cefamandole intravenously followed by cephalexin by mouth
Number of subjects: 193

Group type: COMPARATOR
Intervention: Methicillin intravenously followed by dicloxacillin by mouth
Number of subjects: 193
Study: 11576029

Group type: EXPERIMENTAL
Intervention: Marijuana smoking (days 1-5)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Abstinence from marijuana (days 6-8)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Marijuana smoking (days 9-13)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Abstinence from marijuana (days 14-16)
Number of subjects: 12
Study: 29847382

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg methadone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg methadone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Short-duration opioids (controls)
Number of subjects: 60
Study: 30400790

Group type: EXPERIMENTAL
Intervention: Behavior initiation only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavior initiation + behavior maintenance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 27080282

Group type: EXPERIMENTAL
Intervention: Background volume of 5 mL/h of 0.2% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Background volume of 3.2 mL/h of 0.2% ropivacaine
Number of subjects: 60
Study: 24552980

Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval training (HIT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Higher-volume moderate-intensity continuous training (CT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Control (HIT)
Number of subjects: 22
Study: 22198960

Group type: COMPARATOR
Intervention: Conventional lectures
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Tele-education via videoconferencing
Number of subjects: 89
Study: 20216387

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion targeting 0 ng/ml
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion targeting 2 ng/ml
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion targeting 4 ng/ml
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Effect-site propofol concentration
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: NSRI
Number of subjects: 44
Study: 17373174

Group type: EXPERIMENTAL
Intervention: Triple combination therapy (TCT) - hydroquinone, tretinoin, and fluocinolone acetonide applied once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroquinone alone applied twice daily
Number of subjects: 0
Study: 15358840

Group type: EXPERIMENTAL
Intervention: Thoracic manipulations (n = 43)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Instructions for physiotherapeutic exercises (n = 32)
Number of subjects: 75
Study: 11250991

Group type: EXPERIMENTAL
Intervention: Three cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy
Number of subjects: 812

Group type: COMPARATOR
Intervention: Four cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: 5-day schedule of BEP chemotherapy
Number of subjects: 812

Group type: COMPARATOR
Intervention: 3-day schedule of BEP chemotherapy
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Three cycles of BEP chemotherapy
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Three-day schedule of BEP chemotherapy
Number of subjects: 812
Study: 9549022

Group type: EXPERIMENTAL
Intervention: Iontophoresis of sodium diclofenac
Number of subjects: 40

Group type: COMPARATOR
Intervention: Iontophoresis of sodium salicylate
Number of subjects: 40
Study: 8179130

Group type: EXPERIMENTAL
Intervention: Volume cycled flow generator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bi‐level positive airway pressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spontaneous ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous positive airway pressure
Number of subjects: 0
Study: 3196094

Group type: EXPERIMENTAL
Intervention: Endogenous repair with a prosthetic polypropylene mesh buttress
Number of subjects: 195

Group type: COMPARATOR
Intervention: Local endogenous tissue repair
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Preperitoneal approach with mesh buttress
Number of subjects: 195
Study: 30091545

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding (ACE)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Surface electromyogram biofeedback therapy (sEMGBF)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined treatment (ACE+sEMGBF)
Number of subjects: 90
Study: 28832550

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BoNT) treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BoNT treatment (after 4-7 weeks and again after 11-15 weeks)
Number of subjects: 24
Study: 26306437

Group type: EXPERIMENTAL
Intervention: Laryngeal tubes (LT)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Laryngeal masks (LM)
Number of subjects: 313
Study: 23195913

Group type: EXPERIMENTAL
Intervention: Pictorial image educational strategy
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Teach back educational strategy
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study: 21534239

Group type: EXPERIMENTAL
Intervention: Higher ultrafiltration rates
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Salt intake reduction
Number of subjects: 32
Study: 18455576

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline infusion (control group)
Number of subjects: 14
Study: 16533681

Group type: EXPERIMENTAL
Intervention: Computer-based information-tool
Number of subjects: 75
Study: 15381650

Group type: EXPERIMENTAL
Intervention: Off-pump CABG with collaterals
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: On-pump CABG with collaterals
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Off-pump CABG without collaterals
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: On-pump CABG without collaterals
Number of subjects: 281
Study: 10828923

Group type: EXPERIMENTAL
Intervention: Experimental group instructed to give an insincere effort at 50% of their perceived maximum effort
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group instructed to give a sincere maximum effort
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 9750601

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrocarbonate 1% (n = 17)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrocarbonate 1% with adrenaline 1/200,000 (n = 17)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride 1% (n = 16)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride 1% with adrenaline 1/200,000 (n = 16)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 66
Study: 8443358

Group type: EXPERIMENTAL
Intervention: Digital luminescent radiography (DLR)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Digital luminescent radiography (DLR) with high edge enhancement
Number of subjects: 175

Group type: COMPARATOR
Intervention: Conventional screen‐film system
Number of subjects: 175
Study: 3510268

Group type: EXPERIMENTAL
Intervention: Decongestant-antihistamine mixture (Dimetapp)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 29351861

Group type: EXPERIMENTAL
Intervention: GOALS therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 75

Group type: COMPARATOR
Intervention: GOALS therapy and Treatment as usual
Number of subjects: 75
Study: 27809773

Group type: EXPERIMENTAL
Intervention: Non-invasive ECG monitoring for three weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation history
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Left atrial volume index
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group of age- and gender-matched patients with history of paroxysmal atrial fibrillation prior to stroke (n=55, 67±10 years, 19 female)
Number of subjects: 110